Man Cured of HIV After Sibling Stem Cell Transplant with Rare Mutation

A Norwegian man has achieved sustained remission of HIV following a stem cell transplant from his brother, who carries a rare genetic mutation that confers natural resistance to the virus, according to multiple verified reports published in April 2026. The case, referred to in medical literature as the “Oslo Patient,” marks one of only a handful of documented instances where HIV has been eradicated or rendered undetectable without ongoing antiretroviral therapy through a stem cell procedure.

The patient, a man in his 40s diagnosed with HIV in 2016, underwent the transplant in 2020 after being diagnosed with a blood disorder requiring hematopoietic stem cell transplantation. His brother, identified as a human leukocyte antigen (HLA)-matched donor, was found to carry the CCR5-delta 32 mutation in a homozygous state — meaning he inherited two copies of the gene variant that blocks HIV from entering immune cells. This mutation is known to prevent the virus from using the CCR5 co-receptor to infect CD4+ T cells, a mechanism of resistance seen in a small percentage of people of Northern European descent.

Following the transplant, the patient discontinued antiretroviral therapy under close medical supervision in late 2021. More than three years later, repeated testing has shown no detectable HIV RNA in plasma, no proviral DNA in resting CD4+ T cells and no detectable viral rebound, meeting the criteria for sustained HIV remission. Researchers involved in the case have described the outcome as a functional cure, though they caution that the term “cure” remains reserved for cases with the longest follow-up and most comprehensive tissue sampling.

This case adds to a growing but still extremely rare set of HIV remission outcomes linked to stem cell transplantation. The first well-documented case was the “Berlin Patient,” Timothy Ray Brown, who remained HIV-free for over a decade after two transplants from a CCR5-delta 32 homozygous donor before his death in 2020 from leukemia. Subsequent cases include the “London Patient” and the “Düsseldorf Patient,” all of whom received stem cell transplants for cancer treatment and happened to receive cells from donors with the protective CCR5 mutation.

What distinguishes the Oslo Patient is that the transplant was not primarily performed to treat HIV, but rather to address an underlying hematological condition. The discovery of the brother’s CCR5-delta 32 status came during donor screening, highlighting how serendipitous genetic screening can uncover therapeutic opportunities in the context of allogeneic stem cell transplantation. The brother himself remains asymptomatic and healthy, as individuals with the homozygous CCR5-delta 32 mutation typically show no adverse health effects and have normal immune function despite their resistance to certain strains of HIV.

Experts emphasize that stem cell transplantation is not a viable or ethical strategy for curing HIV in the general population due to the procedure’s high risks, including graft-versus-host disease, infection, and mortality. The intervention is only justified when treating life-threatening conditions such as leukemia or lymphoma, where the potential benefits outweigh the dangers. As such, the approach remains limited to rare clinical scenarios where both a need for transplantation and a genetically compatible donor with the CCR5 mutation coincide.

Nonetheless, the Oslo Patient case provides valuable proof-of-concept support for gene-based strategies aimed at mimicking the CCR5-delta 32 effect. Researchers are investigating approaches such as CRISPR-based gene editing to disrupt the CCR5 gene in a patient’s own hematopoietic stem cells, followed by autologous transplantation. Early-phase clinical trials of such techniques are underway, though they remain experimental and have not yet achieved remission comparable to that seen in donor-transplant cases.

According to the International AIDS Society and amfAR, The Foundation for AIDS Research, fewer than 10 individuals worldwide have been reported to achieve HIV remission or potential cure through stem cell transplantation, all involving donors with the CCR5-delta 32 mutation. Long-term monitoring continues for these cases to confirm the durability of remission and to rule out viral sanctuary in tissue reservoirs such as the gut, brain, or genital tract.

The patient’s medical team, based at Oslo University Hospital, has not disclosed his identity but confirmed in statements to scientific media outlets that he remains off antiretroviral therapy and in good health. They reiterated that while the outcome is encouraging, it does not represent a scalable solution for the nearly 40 million people living with HIV globally. Instead, they advocate for continued investment in antiretroviral therapy access, prevention programs, and curative research that prioritizes safety and broad applicability.

As of April 2026, the Oslo Patient remains in clinical follow-up, with no signs of HIV rebound. His case underscores the importance of genetic screening in donor selection and contributes to the scientific understanding of how HIV can be eradicated under highly specific circumstances. While not a pathway to widespread cure, each such case refines the knowledge base for future gene and cell-based therapies aimed at achieving sustained remission without lifelong medication.